vs

Side-by-side financial comparison of INNODATA INC (INOD) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $72.4M, roughly 1.0× INNODATA INC). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 22.3%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $10.1M). Over the past eight quarters, INNODATA INC's revenue compounded faster (65.3% CAGR vs 31.3%).

Innodata Inc., formerly Innodata Isogen, Inc., is an American company that provides business process, technology and consulting services. The company also provides products that aim to help clients create, manage, use and distribute digital information.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

INOD vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.0× larger
PBYI
$75.5M
$72.4M
INOD
Growing faster (revenue YoY)
PBYI
PBYI
+5.4% gap
PBYI
27.7%
22.3%
INOD
More free cash flow
PBYI
PBYI
$4.3M more FCF
PBYI
$14.4M
$10.1M
INOD
Faster 2-yr revenue CAGR
INOD
INOD
Annualised
INOD
65.3%
31.3%
PBYI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INOD
INOD
PBYI
PBYI
Revenue
$72.4M
$75.5M
Net Profit
$8.8M
Gross Margin
38.3%
69.3%
Operating Margin
15.1%
22.7%
Net Margin
12.2%
Revenue YoY
22.3%
27.7%
Net Profit YoY
-14.2%
EPS (diluted)
$0.26
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INOD
INOD
PBYI
PBYI
Q4 25
$72.4M
$75.5M
Q3 25
$62.5M
$54.5M
Q2 25
$58.4M
$52.4M
Q1 25
$58.3M
$46.0M
Q4 24
$59.2M
$59.1M
Q3 24
$52.2M
$80.5M
Q2 24
$32.6M
$47.1M
Q1 24
$26.5M
$43.8M
Net Profit
INOD
INOD
PBYI
PBYI
Q4 25
$8.8M
Q3 25
$8.3M
$8.8M
Q2 25
$7.2M
$5.9M
Q1 25
$7.8M
$3.0M
Q4 24
$10.3M
Q3 24
$17.4M
$20.3M
Q2 24
$-14.0K
$-4.5M
Q1 24
$989.0K
$-4.8M
Gross Margin
INOD
INOD
PBYI
PBYI
Q4 25
38.3%
69.3%
Q3 25
40.8%
77.7%
Q2 25
39.4%
76.5%
Q1 25
39.9%
77.1%
Q4 24
45.2%
76.4%
Q3 24
40.8%
63.9%
Q2 24
28.7%
77.4%
Q1 24
36.4%
75.5%
Operating Margin
INOD
INOD
PBYI
PBYI
Q4 25
15.1%
22.7%
Q3 25
18.8%
17.6%
Q2 25
15.3%
12.7%
Q1 25
14.2%
8.7%
Q4 24
19.0%
22.6%
Q3 24
21.9%
27.4%
Q2 24
1.0%
-4.6%
Q1 24
5.0%
-5.3%
Net Margin
INOD
INOD
PBYI
PBYI
Q4 25
12.2%
Q3 25
13.3%
16.2%
Q2 25
12.4%
11.2%
Q1 25
13.3%
6.5%
Q4 24
17.4%
Q3 24
33.3%
25.2%
Q2 24
-0.0%
-9.6%
Q1 24
3.7%
-11.0%
EPS (diluted)
INOD
INOD
PBYI
PBYI
Q4 25
$0.26
$0.26
Q3 25
$0.24
$0.17
Q2 25
$0.20
$0.12
Q1 25
$0.22
$0.06
Q4 24
$0.35
$0.40
Q3 24
$0.51
$0.41
Q2 24
$0.00
$-0.09
Q1 24
$0.03
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INOD
INOD
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$82.2M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$107.1M
$130.3M
Total Assets
$168.6M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INOD
INOD
PBYI
PBYI
Q4 25
$82.2M
$97.5M
Q3 25
$73.9M
$94.4M
Q2 25
$59.8M
$96.0M
Q1 25
$56.6M
$93.2M
Q4 24
$46.9M
$101.0M
Q3 24
$26.4M
$96.7M
Q2 24
$16.5M
$96.8M
Q1 24
$19.0M
$107.2M
Total Debt
INOD
INOD
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
INOD
INOD
PBYI
PBYI
Q4 25
$107.1M
$130.3M
Q3 25
$97.3M
$115.3M
Q2 25
$86.7M
$104.7M
Q1 25
$75.5M
$97.1M
Q4 24
$63.5M
$92.1M
Q3 24
$47.7M
$71.1M
Q2 24
$29.0M
$48.5M
Q1 24
$27.6M
$51.0M
Total Assets
INOD
INOD
PBYI
PBYI
Q4 25
$168.6M
$216.3M
Q3 25
$152.9M
$202.9M
Q2 25
$132.6M
$194.9M
Q1 25
$125.2M
$196.2M
Q4 24
$113.4M
$213.3M
Q3 24
$88.2M
$220.7M
Q2 24
$66.0M
$205.0M
Q1 24
$63.6M
$214.1M
Debt / Equity
INOD
INOD
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INOD
INOD
PBYI
PBYI
Operating Cash FlowLast quarter
$12.9M
$14.4M
Free Cash FlowOCF − Capex
$10.1M
$14.4M
FCF MarginFCF / Revenue
13.9%
19.1%
Capex IntensityCapex / Revenue
3.9%
0.0%
Cash ConversionOCF / Net Profit
1.46×
TTM Free Cash FlowTrailing 4 quarters
$35.6M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INOD
INOD
PBYI
PBYI
Q4 25
$12.9M
$14.4M
Q3 25
$18.8M
$9.7M
Q2 25
$4.2M
$14.1M
Q1 25
$10.9M
$3.6M
Q4 24
$17.2M
$15.6M
Q3 24
$11.4M
$11.0M
Q2 24
$-454.0K
$1.0M
Q1 24
$6.8M
$11.2M
Free Cash Flow
INOD
INOD
PBYI
PBYI
Q4 25
$10.1M
$14.4M
Q3 25
$14.5M
$9.7M
Q2 25
$2.5M
$14.1M
Q1 25
$8.5M
$3.6M
Q4 24
$15.0M
$15.6M
Q3 24
$9.9M
$11.0M
Q2 24
$-3.2M
$1.0M
Q1 24
$5.4M
FCF Margin
INOD
INOD
PBYI
PBYI
Q4 25
13.9%
19.1%
Q3 25
23.2%
17.7%
Q2 25
4.3%
26.8%
Q1 25
14.6%
7.7%
Q4 24
25.3%
26.4%
Q3 24
19.0%
13.7%
Q2 24
-9.8%
2.1%
Q1 24
20.5%
Capex Intensity
INOD
INOD
PBYI
PBYI
Q4 25
3.9%
0.0%
Q3 25
6.8%
0.0%
Q2 25
2.9%
0.0%
Q1 25
4.0%
0.1%
Q4 24
3.7%
0.0%
Q3 24
2.8%
0.0%
Q2 24
8.4%
0.0%
Q1 24
5.1%
0.0%
Cash Conversion
INOD
INOD
PBYI
PBYI
Q4 25
1.46×
Q3 25
2.25×
1.10×
Q2 25
0.59×
2.41×
Q1 25
1.40×
1.21×
Q4 24
1.67×
Q3 24
0.65×
0.54×
Q2 24
Q1 24
6.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons